Industry news
-
Digital Therapeutics Can Break Down Barriers to Innovation to Benefit Patients
04 July 2019
There is rapidly growing and sizeable evidence which shows that innovating is the most important factor in pharmaceuticals. The industry is a field which itself has developed and evolved on the basis of disruption and innovation.
-
Pharma Invests £377m in UK R&D Collaborations, New ABPI Figures Showed
04 July 2019
New figures published by the ABPI show that pharma invests £377m in UK R&D collaborations, working with healthcare professionals and organisations to improve care for NHS patients.
-
Pharma takes Wi-Fi targeting to the doctor's office to reach waiting patients on their smartphones
04 July 2019
Checking your phone at the doctor’s office? Don’t be surprised if you get an ad for a drug you can talk to your doctor about. Data-as-a-service provider Semcasting is using IP address targeting to serve messages to patients’ smartphones while they’re waiting at appointments.
-
Pharma shells out $3B to doctors and hospitals—with Roche, Sanofi leading: CMS
03 July 2019
As massive marketing crackdowns and kickback lawsuits circulate through U.S. courtrooms, scrutiny on pharma's financial ties to healthcare providers has never been higher. But instead of scaling back its payments to docs and hospitals last year, Big Pharma leaned in even further.
-
Pfizer Received FDA Approval for Avastin® Biosimilar
02 July 2019
Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer.
-
What to Expect from Russian GMP Inspection
02 July 2019
Inspectors from Russia come on behalf of the so called Certification Center within the Ministry of Industry and Trade (MoIT). The MoIT will – after successful inspection – issue a GMP Certificate. This certificate has been required for new submissions sincec 2016 and for renewals/variations since 2017. No products without a Russian GMP certificate can be exported to Russia. If a site does not pass the inspection, CAPAs should be completed and a new submission with supporting documents will be required.
-
Pharma back in hot seat as 2020 presidential election gets into gear
01 July 2019
Once again, we're watching presidential debates with too many candidates to fit on one stage. And once again, pharma is proving itself an easy target. As the first Democratic presidential debates kicked off this week, candidates took numerous shots at drugmakers in an early sign the industry will face plenty of tough questions throughout the 2020 cycle. The candidates blasted corporate power in the U.S. in general—and pharma in particular, using words like "corruption" and "greed."
-
Cue the ‘revolving door’ criticism: Former FDA commissioner Gottlieb joins Pfizer’s board
01 July 2019
When former FDA commissioner Scott Gottlieb, M.D., resigned back in March, he said he wanted to spend more time with his family. Since then, Gottlieb has nabbed a partnership at a VC firm and a think tank fellowship. And now, less than three months since his last day regulating pharma, Gottlieb has joined Pfizer, one of the biggest companies in the business.
-
Pharma's got its chief digital officers. Now let's see results
28 June 2019
Sanofi’s newly appointed chief digital officer, Ameet Nathwani, M.D., isn’t surprised to see CDOs proliferating across Big Pharma. But he does think he and his counterparts have some work to do if they want to stick around. Nathwani, part of a recent wave of CDO appointments at drugmakers including GSK, Novartis and Merck, says “a late realization that we were slow” has helped drive pharma’s recent push toward digital.
-
Drug Production to be Launched in Moscow Special Economic Zone
27 June 2019
An agreement clearing the pharmaceutical company R-Opra to manufacture drugs in the Technopolis Moscow special economic zone was concluded at the St. Petersburg international economic forum. Under the agreement signed the company will make drugs for the hospital and drug reimbursement segments to treat cardiac, oncological, psychiatric and breathing system disorders, as well as multiple sclerosis and chronic renal insufficiency.
